Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plasmodium falciparum membrane, specifically during the erythrocytic stage, is a crucial target for antimalarial strategies utilizing reactive oxygen species (ROS). ROS, generated by antimalarial drugs like artemisinins or by the host immune response, induce oxidative damage to membrane lipids and proteins, leading to increased permeability, mitochondrial dysfunction, and ultimately parasite death. The parasite's limited antioxidant defenses, particularly the absence of catalase and glutathione peroxidase, make it vulnerable to oxidative stress. PfATP6/SERCA is a proposed molecular target.
Lipid peroxidation, protein alkylation, mitochondrial depolarization, and increased membrane permeability induced by reactive oxygen species.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum Membrane (via Reactive Oxygen Species) (Pf Membrane (ROS)).